I. INTRODUCTION
In 2009, the Journal of Psychiatric Research published an article that linked abortion to psychiatric disorders. 1 2 The study was widely cited among abortion opponents, 3 and several states enacted legislation requiring that women seeking abortions receive counseling that includes warnings about potential long-term mental health problems. 4 In 2012, however, the study was discredited by scientists who scrutinized its design and found that it was severely flawed. 5 The original researchers neglected to compare women with 500 AMERICAN JOURNAL OF LAW & MEDICINE VOL. 39 NO. 4 2013 challenges of inferring causal effects correctly. 16 Much has been written about EHR privacy risks, but this paper makes a different contribution to the legal literature by focusing on what can go wrong in the process of biomedical data analysis and what precautions must be taken to avoid critical mistakes. It sheds much-needed light on the problems of naïve or irresponsible use of biomedical databases, and these problems are likely to become much more common and pressing in the near future. The data-use pitfalls we discuss are familiar to competent biomedical researchers but must be understood by lawyers, bioethicists, policymakers, and anyone else who will rely on research results. We s and/or genomic information as well as decentralized, federated database systems. 17 Thus, in this paper, we address non-interventional research, that is, research that is based on - 18 We do not intend to comment on clinical studies in which investigators conduct experiments using human subjects 19 or on research involving the administration of questionnaires or surveys.
Observational studies are relevant to the law because their outcomes can lead to regulatory enforcement actions or to legislative changes, and they can be used as evidence in litigation. For example, observational studies may reveal that use of a medication or device causes patients to suffer serious adverse events, and this discovery may induce the Food and Drug Administration (FDA) to intervene. 20 Observational studies may also uncover statistical associations between illnesses and exposure to certain substances or between diseases and genetic variations. 21 Reports of these associations may be used in litigation by both plaintiffs and defendants. 22 Plaintiffs may file tort cases against product manufacturers, and toxic tort defendants 16 Pamela N. Peterson & Paul D. Varosy, Observational Comparative Effectiveness Research: Comparative Effectiveness and Caveat Emptor, 5 CIRCULATION CARDIOVASC. QUALITY & OUTCOMES 150, 151 (2012) ( importance) . 17 See infra note 37 and accompanying text for definition of federated database system. In other contexts, biomedical databases can also consist of data collected from large-scale clinical studies. Prakash M. Nadkarni, Managing Attribute Value Clinical Trials Data Using the ACT/DB Client Server Database System, 5 J. AM. MED. INFORMATICS ASS N 139, 139 (1998) 23 News outlets frequently report new research findings. Press reports often trumpet the discovery that factor A condition B. The availability of large biomedical databases greatly facilitates the discovery of such associations. However, the nature of such data can complicate the determination of whether factor A actually causes or contributes to condition B. We address three main reasons for a cautious approach to incorporating record-based research into the law.
First, the data contained in biomedical databases may be of poor quality, incomplete, or even deliberately distorted. 24 For example, a recent New York Times article reported that the automated features of EHR systems make it easy for doctors to exaggerate the care they provided for purposes of Medicare reimbursement. 25 Doctors can simply click on menu items or copy and paste narrative in order to justify billing, and some lack scruples with respect to overstating or even fictionalizing what occurred during clinical encounters. 26 Such practices not only defraud Medicare, but also compromise the accuracy of EHRs. Moreover, they can systematically bias research results.
Second, valid causal analysis is much more difficult with observational data than with data from well-designed and well-executed randomized experiments or clinical trials. 27 Unfortunately, having does not necessarily ameliorate this problem. The challenges of properly analyzing observational data and making appropriate causal inferences 28 are illustrated in a -Defined 29 The researchers critique previous observational studies of obesity and mortality and conclude that they were flawed because they failed to specify what interventions were used to reduce body mass index (BMI). Different methods of changing BMI (e.g., surgery, diet, exercise) are associated with different risk levels for patients, and mortality may actually be associated with the treatment rather than the underlying obesity in some cases. 30 Thus, researchers cannot reach meaningful conclusions about the benefits of reducing BMI without knowing what interventions were used to achieve this goal in each instance. 31 23 Id. at 339-40 (explaining that epidemiological evidence has already played an important role in many mass tort cases);; Steve C. Gold, The More We Know, the Less Intelligent We Are? How Genomic Information Should, and Should Not, Change Toxic Tort Causation Doctrine, 34 HARV. ENVTL. L. REV. 369, 412-17 (2010) ( injuries) . 24 See infra Part III. 25 Reed Abelson et al., Medicare Bills Rise as Records Turn Electronic, N.Y. TIMES, Sept. 21, 2012, at A1, A3, http://www.nytimes.com/2012/09/22/business/medicare-billing-rises-at-hospitalswith-electronic-records.html?_r=0. 26 Id. 27 See infra Part IV. 28 Samantha Kleinberg & George Hripcsak, A Review of Causal Inference for Biomedical Informatics, 44 J. BIOMED. INFORMATICS 1102 , 1102 Answer Causal Questions, 32 INT L J. OBESITY S8 (2008) . 30 Id. at S13. 31 Id.
502
AMERICAN JOURNAL OF LAW & MEDICINE VOL. 39 NO. 4 2013 actions, behaviors, or policies, on the one hand, and outcomes of public interest, on the other hand, for the purpose of manipulating public opinion and swaying policy decisions. 32 The risk of misinterpretation of such results by interested parties is high if they are not well-trained and scrupulous researchers. Research about the purported link between abortion and psychiatric disorders, discussed above, demonstrates this potential danger. 33 Pro-life advocates used questionable scientific data to promote a controversial legislative agenda.
The paper proceeds as follows. Part II provides background information. It describes ongoing efforts to build biomedical databases and analyzes the relevance of observational studies to law and public policy. Part III analyzes common shortcomings of biomedical data that should give analysts and the public pause. These include input errors, incomplete or fragmented records, and flaws in data coding or standardization.
Part IV provides an in-depth discussion of causal inference and of biases affecting observational studies. It analyzes the challenges of inferring causation in observational studies, including the problems of selection bias, confounding bias, and measurement bias. Indeed, confounding bias and selection bias will likely be fundamental concepts in legal reasoning in big data environments. Part V addresses the potential use of observational study outcomes for purposes of furthering political, social, and economic agendas.
Finally, Part VI analyzes the factors that contribute to sound research and provides guidance for policymakers and litigants seeking to determine whether particular research outcomes are reliable. The quality of digitized research databases and the studies that grow out of them will depend not only on good technology, but also on persistent human efforts to safeguard the integrity of research projects. Technological advances are needed to enhance interoperability, data capture, dataextraction capabilities, and system usability. In addition, clinicians and patients can partner to assess the validity of the data contained in EHRs, and investigators must be scrupulous about study design, analysis, and publication. This Part also describes and critiques the use of causal inference diagrams, which have received little attention in the legal literature but is increasingly common in other fields. 34 Equally important is ensuring that the legal community, journal editors, and the public at large are not misled by those who appear to engage in scientific endeavors but who in truth misuse evidence to promote their own political, social, or economic agendas. Legal practitioners must understand the complex issues raised by big data in order to play a useful role in protecting the public interests. To this end, we recommend the development of law school and other educational programs about the challenges of observational data analysis and causal inference.
II. BACKGROUND
Researchers and other analysts may gain access to large-scale collections of biomedical data in two primary ways. First, health information can be collected into 32 See infra Part V. 33 See supra notes 1-6 and accompanying text. large databases and de-identified to protect patient privacy. 35 Such databases could be limited to particular hospital systems, be expanded to cover entire regions, or even be national in scope. 36 I databases, but they allow researchers to submit statistical queries through a standard web service in order to obtain summary statistics for a study population. 37 Trusted third-party aggregators can operate the query service. 38 Many large biomedical databases and federated systems already exist and are used for non-treatment purposes. 39 zation of health information outside the clinical setting. 40 This Part describes a sample of data-collection initiatives. It also discusses how experts in the biomedical research, quality assessment, public health, and litigation arenas may utilize EHR data.
A. ONGOING INITIATIVES TO CREATE BIOMEDICAL DATABASES
The Federal Government has clearly recognized the usefulness of biomedical databases and enthusiastically supports database projects. The Obama Administration has announced an overarching effort cal Big Data ). 41 
cutting-
;; to employ those technologies to promote scientific discovery, improved national security, and education;; and to expand the workforce skilled in these technologies. 42 Big Data will involve six federal agencies and departments and is estimated to cost $200 million. 43 At the same time, many federal entities are independently building health information databases. 45 For example, the Department of Veterans Affairs (VA) is registering volunteers for its Million Veteran Program to construct a large research framework that will link anonymized blood samples and health information. 46 The VA plans to study how genes affect health and disease. 47 The Centers for Medicare & Medicaid Services created a research database called the Chronic Condition Data Warehouse. 48 The database provides researchers with information about Medicare and Medicaid beneficiaries, claims for services, and assessment data. 49 In May of 2008 the FDA launched the Sentinel System in order to facilitate postproblems. 50 The Sentinel initiative aims to enable the FDA to access health information from 100,000,000 individuals. 51 Sentinel is a federated system that will allow the FDA to send queries concerning potential product-safety problems to data holders such as Medicare, the VA, and major medical centers. 52 Using special analysis programs, the data holders will assess their records and send summary responses to the FDA. 53 A large number of private-sector initiatives are ongoing as well. Geisinger Health Systems operates MedMining, a company that extracts EHR data, deidentifies it, and offers it to researchers. 54 The data sets that MedMining delivers to 55 Explorys has formed a large healthcare database derived from financial, administrative, and medical records. 56 It has partnered with major healthcare organizations such as the Cleveland Clinic Foundation and Summa Health System to aggregate and standardize health information from ten million patients and over available on the Amazon Web Services cloud. Jeannie Baumann, White House Initiative Aims to Improve Use of Large Digital Databases for R & D, 11 MED. RES. L. & POL Y 217, 217-18 (2012 thirty billion clinical events. 57 Using a cloud-computing platform, it provides customers with big data to use for research and quality improvement purposes. 58 The electronic Medical Records and Genomics Network (eMERGE) is a consortium of five institutions with DNA repositories linked to EHRs that supply relevant clinical data. 59 The National Human Genome Research Institute supports eMERGE, and the National Institute of General Medical Sciences provides it with additional funding. 60 genome--wide association analysis. 61 A primary purpose of eMERGE is to develop approaches to conducting large-scale genetic research using DNA biobanks that are connected to EHR systems. 62 The Distributed Ambulatory Research in Therapeutics Network Institute (DARTNet) is a collaboration among nine research networks, including 85 healthcare organizations and over 3,000 clinicians across the United States. 63 The first DARTNet federated network, eNQUIRENet, was created in 2007 and funded by the Agency for Healthcare Research and Quality. 64 DARTNet members allow data from their EHRs to be captured, de-identified, coded, standardized, and stored in a Clinical Data Repository (CDR) within each entity that also connects to billing, lab, hospital, and prescription databases. 65 CDR data are then transferred to a second database that makes de-identified information available to researchers through a secure web portal. 66 Other agencies and organizations are building electronic registries and databases that focus on specific disease categories in an effort to promote research and quality improvement endeavors. These include the Cancer Biomedical Informatics Grid, 67 57 Id. GENOME.GOV, http://www.genome.gov/27540473 (last updated Aug. 29, 2013 Large-scale biomedical databases may be used for many purposes. This section addresses a variety of ways in which they are likely to be used by researchers, regulators, public health officials, commercial entities, and lawyers. As we have indicated, biomedical databases constitute an important tool for medical researchers. They are also used by healthcare providers who conduct quality assessment and improvement activities, and they assist the FDA in monitoring the safety of drugs and devices on an ongoing basis. In addition, biomedical databases can support public health initiatives and allow litigants in tort cases to develop evidence concerning causation and harm.
Scientific Discovery
Biomedical databases can enable researchers to conduct large-scale observational studies that will fill existing knowledge gaps. Even today, clinicians practice medicine with an unsettling degree of uncertainty. 71 According to some estimates, doctors know that the treatments they prescribe will be effective in only twenty to twenty-five percent of cases. 72 Database proponents believe that recordsbased research could contribute substantially to the resolution of these uncertainties. 73 Biomedical databases could allow researchers to access a vast quantity of information about millions of patients who are treated in varied clinical settings, have diverse attributes, and live in different regions of the country. 74 Available The data reviewed in database studies, consequently, may be far more abundant and comprehensive than the data generated by clinical trials, 75 which are rigorously controlled and often involve fewer than 3000 patients. 76 Large-scale studies have the potential to better reflect the entire population and expose how treatments are actually used in a large variety of medical facilities. 77 They also tend to enhance the precision of statistical analyses. 78 If the researchers aim to show whether a specific treatment achieves the desired benefits, they may reasonably choose to conduct a randomized clinical trial to ensure that uncontrolled variables that influence outcomes, such as age or drug interactions, do not confound the study. 79 However, observational studies may be needed to determine whether the results of randomized clinical trials that involved only a few thousand patients can be generalized to the patient population at large and to realistic treatment situations rather than carefully controlled ones. 80 Furthermore, observational research based on medical records will often be sufficient to determine 81 It is also useful for generating and testing speculative hypotheses that could lead to important insights. 82 AM. MED. ASS N 122, 122-24 (1994) . 79 Hoffman & Podgurski, supra note 8, at 98-99;; Jan P. Vandenbroucke, The HRT Controversy: Observational Studies and RCTs Fall in Line, 373 LANCET 1233 , 1234 . 80 Stuart L. Silverman, From Randomized Controlled Trials to Observational Studies, 122 AM. J. MED.
trolled trial data with information on efficacy, safety, and patient compliance in a population of real-supra note 71, of what is proved to be effective for selected groups of patients versus the infinitely complex clinical 81 Jan P. Vandenbroucke, Observational Research, Randomised Trials, and Two Views of Medical Science, 5 PLOS MED. 339, 341 (2008) , available at http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0050067 (explaining that adverse effects are generally unexpected and unpredictable, and therefore are not subject to and can be determined through observational studies). See infra notes 244-247 and accompanying text for discussion of confounding by indication. 82 Vandenbroucke, supra down the wrong alley and detecting why it is wrong, or playing with a seemingly useless hypothesis;; 508 AMERICAN JOURNAL OF LAW & MEDICINE VOL. 39 NO. 4 2013 less costly and time-consuming than experimental research, especially when researchers obtain the required data from existing databases. 83 The benefits of observational studies are illustrated by the highly publicized controversy concerning an alleged association between vaccination and autism. In 1998, Dr. Andrew J. Wakefield and colleagues published a study in the Lancet that suggested a link between autism and the measles, mumps, rubella (MMR) vaccination. 84 The findings were based on testing of twelve children with developmental disorders. 85 placed upon these fi 86 after large-scale observational research involving the review of hundreds of records of autistic children in the United Kingdom found no causal association between the MMR vaccine and autism. 87 Consequently, the Centers for Disease Control and Prevention (CDC) now reassures the public on its website that there is no link between autism and vaccines. 88 For purposes of genetic research, EHRs can be coupled with genetic samples and data so that analysts can obtain detailed and comprehensive characterizations of study subjects. 89 An increasingly common form of big-data observational research is genome-wide association studies (GWASs). 90 GWASs compare the DNA of individuals with a particular disease or condition to the DNA of unaffected individuals in order to find the genes involved in the disease. 91 A government website catalogues published GWASs and on October 24, 2013, listed 1,727 studies that had been conducted since 2005. 92 Critics have noted that although GWASs led to the discovery of many genetic variants that are statistically associated with disease;; thus far, most of the variants appear to have a minimal effect on disease and 351 LANCET 637, 641 (1998 353 LANCET 2026 353 LANCET , 2026 353 LANCET -29 (1999 Method, 13 BIOSTATISTICS 195, 196 (2012) . 91 Dictionary of Cancer Terms, NAT L CANCER INST., http://www.cancer.gov/dictionary?cdrid=636779 (last visited Oct. 25, 2013) . 92 NAT L HUMAN GENOME RES. INST., A Catalog of Published Genome-Wide Association Studies, GENOME. GOV, http://www.genome.gov/gwastudies/ (last visited Oct. 26, 2013) .
THE USE AND MISUSE OF BIOMEDICAL DATA 509 explain only a small percentage of heritability. 93 Others assert that many GWASs to date have been compromised by serious design flaws. 94 However, GWASs remain an important scientific endeavor and will likely lead to significant discoveries in the future.
A different method of scanning the genome is genome-wide linkage studies (GWLSs). Researchers perform GWLSs when they are focusing on biologically related individuals and a phenotype, such as breast cancer, that some but not all of the family members have. 95 Based on patterns of correlation between alleles 96 and disease found within families, researchers attempt to detect broad DNA regions in which disease susceptibility loci are most likely to be found. 97 The Federal Government and many medical experts have embraced the objective of conducting extensive comparative effectiveness research (CER). 98 The Patient Protection a evaluating and comparing health outcomes and the clinical effectiveness, risks, and benefits of 2 or more medical treatments, services, and items . . . . 99 CER can be conducted in part through observational studies, which can be particularly illuminating because they reflect actual usage of treatments. 100 The outcomes of CER and other observational studies may ultimately enable the healthcare community to alleviate human suffering more effectively, reduce medical costs, and 101 2. Quality Assessment and Improvement Healthcare providers routinely collect quality measures concerning the services they provide. 102 Polymorphisms, 14 MOLECULAR PSYCH. 786, 786-87 (2009) . 96 NAT L HUMAN GENOME RES. INST., Allele, GENOME.GOV, http://www.genome.gov/glossary/?id=4 (last visited Oct. 25, 2013 103 Medical facilities and government authorities conduct a variety of oversight activities. Providers may seek data for internal quality assessment purposes in order to judge the success of particular initiatives. 104 Insurers may require facilities to submit process and outcome information in the context of pay-for-performance programs. 105 In addition, the Centers for Medicare and Medicaid Services (CMS) and many state governments require quality measurements and public reporting. 106 A -available data about the quality of care at over 4000 hospitals. 107
Post-Marketing Surveillance of Drugs and Devices
EHR databases could assist the FDA in regulating drugs and devices. 108 The Food and Drug Administration Amendments Act of 2007 (FDAAA) 109 expanded the deployed in the marketplace. 110 Evidence concerning drug safety in the postmarketing period will be developed in significant part through observational studies. 111 Such studies will be made possible through the Sentinel System, the national health data network discussed previously. 112 While clinical trials constitute the gold standard for purposes of FDA drug approval, 113 Gaps, 366 NEW ENG. J. MED. 875, 875 (2012) . 125 See id. 126 See id.;; Robert G. Hauser, Here We Go Again Another Failure of Postmarketing Device Surveillance, 366 NEW ENG. J. MED. 873, 873-74 (2012) .
Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), are a valuable tool because they collect clinical data about patients after their devices have been implanted. 128 Ideally, automated surveillance systems would trigger alerts if the frequency of adverse events related to a device exceeded a designated threshold 129 so that healthcare providers could react appropriately and prevent further harm to patients.
Public Health Initiatives
Federal regulations and public health projects demonstrate that biomedical databases will also be used to promote public health goals. Healthcare providers who wish to receive government incentive payments to support EHR system implementation eff the EHR functions they must be able to perform. 130 These include sending certain lab results and reports electronically to public health agencies and providing electronic information to immunization registries. 131 Public health authorities are meant to collect the submitted information in databases and use it to conduct disease surveillance and respond to public health threats. 132 Some public health entities have already launched programs that use electronic data. 133 Examples are programs that track information about vaccine-related adverse events, sexually transmitted diseases (STDs), and HIV/AIDS. 134 The Centers for Disease Control and Prevention is collaborating with eight large health maintenance organizations to detect adverse events associated with vaccinations. 135 The Vaccine Safety Datalink (VSD) has access to large clinical data repositories that are linked together and provide information about almost 2.5 percent of the U.S. population. 136 Information garnered by the VSD could potentially lead to changes in state vaccination laws. 137 New York City implemented an EHR system in 2004-05 for its ten Department of Health and Mental Hygiene public clinics that treat patients with STDs. 138 The EHRs ha 139 Several evaluations led the city to alter its policies in order to increase opportunities for STD testing and access to care. 140 The Louisiana Public Health Information Exchange (LaPHIE) links statewide public health surveillance information with individual EHR data. 141 LaPHIE alerts clinicians when an HIV-positive patient who has not received HIV care for over twelve months presents at any healthcare facility for any reason, so that providers may pursue HIV care with that patient. 142 Such information exchange networks can constitute a valuable tool for combating infectious disease and assist states in fulfilling their public health responsibilities. 143
Litigation
If databases of de-identified EHR information become publicly available for non-clinical purposes, litigants who seek to prove causation or harm in mass tort cases may mine them for evidence. 144 Several such databases already exist. For example, California, Texas, and Vermont have databases of inpatient hospital discharge data. 145 Selected datasets that do not directly identify patients but include diagnoses, treatments, drug intake, and other details are available for purchase by the public. 146 Private sector enterprises, such as MedMining and Strategic Healthcare Programs, also offer requestors access to their health information databases. 147 Data availability has been promoted in academic circles as well. Professor Marc Rodwin argues that patient data should routinely be treated as public property. 148 He posits that federal law should require clinicians, hospitals, and insurers to report deidentified patient data to public authorities who would create aggregate databases that would be available to private entities, subject to public oversight. 149 Litigants have already used epidemiological evidence in many mass tort cases, -magnetic radiation, 150 Epidemiological data is most 139 Id. & TECH. 103, 124 (2008 often employed with respect to causation, and it is not unusual for the courts to accept it as persuasive. 151 In the future, observational studies based on biomedical databases may frequently aid in developing compelling epidemiological evidence.
While plaintiffs will attempt to prove causation through database analysis, 152 For roducts. 153 Researchers have found that genetic variants influence conditions that are often at the center of legal disputes. Genetic 154 of developing lung cancer or chronic obstructive pulmonary disease, 155 and of suffering from carpal tunnel syndrome. 156 Commentators predict that defendants will Gold, supra note 23, at 412;; Diane E. Hoffman & Karen H. Rothenberg, Judging Genes: Implications of the Second Generation of Genetic Tests in the Courtroom, 66 MD. L. REV. 858, 867 (2007) ;; Gary E. Marchant, Genetic Data in Toxic Tort Litigation, 14 J.L. & POL Y 7, 12 (2006) ;; Susan Poulter, Genetic Testing in Toxic Injury Litigation: The Path to Scientific Certainty or Blind Alle y?, 41 JURIMETRICS J. 211, 217-20 (2001 161 It is also possible that self-appointed watchdogs may mine public databases to determine whether exposure to particular products or substances results in adverse health consequences. Based on their findings, they could publicize supposed problems, demand government intervention or encourage lawyers to initiate litigation.
III. LIMITATIONS OF BIOMEDICAL DATABASES
Biomedical databases constitute a potentially invaluable research resource, but researchers, analysts, and other stakeholders must appreciate that existing EHRs and genomic data often contain errors, are incomplete, or suffer from other shortcomings. While any collection of research data may be contaminated by inaccuracies, biomedical databases may be particularly flawed. The information in EHRs is initially collected for clinical and billing purposes, and thus it might be illsuited for research. 162 Moreover, the sheer volume of information contained in large biomedical databases 163 and the complex analytical methods and tools required to conduct large-scale observational studies 164 create myriad opportunities for the introduction of errors and omissions. While improved technology may remedy many database shortcomings in the future, 165 these deficiencies are currently of serious concern. This section examines a variety of potential data quality problems.
A. DATA ENTRY ERRORS EHR databases may be tainted by data entry errors. Digitization can prevent some data quality problems, such as those associated with illegible handwriting, 166 but it does not remove the risk that entries in patient records will be incorrect. Inaccurate clinical data will become inaccurate research data if the EHRs are imported to research databases or are accessible to investigators through federated systems.
Clinicians who enter data into records can easily invert numbers or mistype words, select wrong items from a menu, check the wrong box, obtain inaccurate information from patients, and make other data entry mistakes. 167 and some of these errors are unique to digitized rather than paper records. For example, in order to save time, clinicians may copy and paste relevant narrative from prior visit notes and place it in the wrong location in the chart or fail to carefully edit or update it. 169 They may also neglect to save notes in unclosed charts, or they may misinterpret lab results that are displayed in a confusing fashion 170 Several studies have attempted to estimate error rates in EHRs. A study of a number of research databases containing information about oncology patients at an academic medical center found error rates of 2.3-26.9%. 171 Errors were attributable to data entry mistakes, misinterpretation of hard-copy documents when information was typed into the database, and perpetuation of errors that were contained in the original paper documents and then copied during the data entry process. 172 Another publication found an average error rate of 9.76%. 173 A small study involving twentyfive Israeli physicians revealed that over sixty percent of participants admitted that they had or selected an incorrect item from an electronic menu of choices, though pharmacists often served as a safeguard against actual treatment mistakes. 174 A different study highlighted the frequency of medication discrepancies in hospitals. 175 The study identified 2066 medication discrepancies relating to 180 patients, of which 939 were unintentional and therefore constituted errors. 176 Among the errors, 257 instances had the potential to harm patients. 177 The majority (72%) of errors stemmed from mistakes made while taking preadmission medication histories, and the remainder was caused by failure to reconcile medication history with discharge orders. 178 MED. 1414 MED. , 1414 MED. (2008 . 176 Id. at 1416. 177 Id. 178 Id. 179 Id. at 1417. THE USE AND MISUSE OF BIOMEDICAL DATA 517 Data errors can skew the outcomes of research studies. A study that focused on 180 Other researchers have confirmed that even error rates as small as one to five percent could cause significant inaccuracies in mortality and adverse event estimates. 181 Database operators and analysts also cannot ignore the possibility that in the worst-case scenario, hackers could access biomedical databases and intentionally introduce errors or alter records. 182 Data errors that do not occur at random are especially problematic because they may systematically bias research outcomes. 183 Like EHR databases, genome-sequencing projects have been plagued by genome annotation errors. 184 One study found that the frequency of misannotation has grown during the years 1993 to 2005 and that the protein sequence databases that were studied exhibited levels of annotation errors spanning from zero to over sixty percent. 185 186 and they can significantly impact other aspects of organisms. 187 Experts have called for the development of guidelines and standards to improve the submission, retrieval, processing, and analysis of genomic data. 188
B. INCOMPLETE OR FRAGMENTED DATA
Incomplete or fragmented data may also compromise the reliability of EHR database information. At times, EHR data does not include all of the information needed for particular research projects. 189 Clinicians generally do not approach the task of EHR documentation with research studies in mind. 190 Data, 11 BMC BIOINFORMATICS 485, 485 (2010) Out-of-Hospital Clinical Research, 19 ACAD. EMERGENCY MED. 217, 224 (2012) . instance, a manual review of EHR data from the New York-Presbyterian Hospital clinical data warehouse revealed that when pneumonia patients died in the in the electronic health record, the patient appeared to be healthy other than the 191 Data about treatment outcomes is particularly likely to be missing. 192 For example, a patient discharged from an emergency room may not seek further care at all or may later visit a physician who has a different EHR system, making it impossible to track whether the treatment was effective over the long-term. 193 The absence of information about treatment outcomes in an EHR is difficult to interpret. It could mean that the therapy cured the patient, and she did not report the positive result because she required no follow-up, but it could also mean she experienced no relief, or her condition deteriorated and she went to a specialist or another doctor. Data fragmentation often exists because different facilities have EHR systems that are not interoperable. 194 Thus, seriously ill patients who are treated at multiple medical centers as their disease progresses may have their records divided among several EHR systems, and these are unlikely to be integrated into a single research database. 195
C. DATA CODING, STANDARDIZATION, AND EXTRACTION
Medical data in EHRs is often coded, but the coding can be inconsistent, incorrect, or misleading. 196 Healthcare providers code data in accordance with the International Classification of Disease, version 9 (ICD-9), developed by the World Health Organization, and the Current Procedural Terminology, version 4 (CPT-4), formulated by the American Medical Association to record procedures and laboratory tests. 197 By 2014, healthcare providers will be required to switch to ICD-10, which has approximately 155,000 codes rather than Hripcsak et al., supra note 180, at 50. It is especially challenging to analyze the effects of treatments or exposures in the face of data with missing items if they are not missing completely at random. Such non-random omissions create the potential for biased results. Craig H. Mallinckrodt et al., Assessing and Interpreting Treatment Effects in Longitudinal Clinical Trials with Missing Data, 53 BIOLOGICAL PSYCHIATRY 754, 755 (2003 , 2006) . 195 Botsis et al., supra note 40, at 4 (stating that the EHR system that was mined for purposes of the study did not contain records of patients who were transferred to dedicated cancer centers because of the severity of their disease or who had initially been treated elsewhere). 196 Naren Ramakrishnan et al., Mining Electronic Health Records, COMPUTER 95, 96 (2010) 1,  2013) ;; ICD-10 Code Set to Replace ICD-9, AM. MED. ASS N, http://www.ama-assn.org/ama/pub/physician-resources/solutionsmanaging-your-practice/coding-billing-insurance/hipaahealth-insurance-portability-accountabilityact/transaction-code-set-standards/icd10-code-set.page (last visited Oct. 22, 2010) .
EHR systems also provide their own selection menus with various codes to facilitate data entry. 199 Critics have charged that healthcare providers often use coding to maximize billing opportunities, rather than to build the most accurate record possible. 200 Menus and lists built into EHR systems may encourage clinicians to charge for more services by suggesting items for which they can bill and making it easy to click on boxes for billing purposes. 201 services provided to Medicare patients was very common and may account for as billion annually. 202 offices to make strategic choices that will enhance their revenues. 203 The Federal Government has recognized the problem and is reportedly investigating Medicare fraud related to upcoding. 204 Several studies have specifically identified coding inadequacies as an obstacle to secondary use of EHR data. 205 According to one source, ICD-9 codes are not specific enough for cancer to enable researchers to distinguish primary tumors from metastatic ones. 206 ICD-9 coding deficiencies will remain a problem even after the adoption of ICD-10 because existing patient records will contain ICD-9 codes. 207 A British study examined the separate codes offered by a general practice EHR system and concluded that the coding screen did not clarify which designation was appropriate for acute rather than more moderate disease and which range of codes indicate the presence of chronic obstructive pulmonary disease. 208 In addition, the study found that different physician groups use different codes to label the same type of patient, so, for example, some patients receiving medication to combat osteoporosis were not coded as having osteoporosis. 209 Discrepancies and variability in quality of data may be attributable to a number of factors. According to one source, record-keeping was found to be more meticulous if it was relevant to financial gain, contractual obligations, or external 520 AMERICAN JOURNAL OF LAW & MEDICINE VOL. 39 NO. 4 2013 viewers, and more sloppy if it was used internally only. 210 In addition, the existence of multiple fields for documentation and variable practices among different personnel (e.g., documenting scheduled date versus actual date of an appointment) can generate irregularities. 211 inconsistent use of terms, phrases, and abbreviations. To illustrate, the abbreviation 212 If the context is not clear from the EHR, a reader might fail Further challenges arise from the existence of free text narrative in EHRs. EHR systems allow providers to enter both coded information and unstructured, naturallanguage notes about patients. 213 Important information that is not captured in structured data may be contained in notes, and such information is much more difficult to extract accurately from EHRs for secondary use. 214 As an example, database mining may fail to reveal a link between worsening asthma and smoking if the progression of asthma is coded but smoking history is described only in free-text clinical notes. 215 Similarly, family history and information about adverse reactions to drugs are likely to be presented in narrative form rather than in coded form. 216 Experts may employ natural-language processing tools to extract data from free-text narrative, but these techniques are still developing and are often imperfect. 217 If diagnoses, measurements, or medical histories contained in EHRs are not standardized or are inaccessible because they do not appear in structured form, database contents may be inadequate for secondary uses. 218 Similarly, if medical vocabulary is not harmonized, researchers may misunderstand or be unable to make sense out of database records.
D. ERRORS DUE TO SOFTWARE FAILURES
Errors in research data and in the results of computer analysis can also result from incorrect processing by defective software. EHR systems, like any complex software system, may contain unrecognized or unrepaired software defects. 219 Such value that is incorrect but is nevertheless plausible may not be discovered and hence may remain in Even if the raw data is correct, errors may arise during data analysis due to defects in the software used to conduct the analysis. 220 This is particularly likely if 210 Ancker et al., supra note 40, at 61. MED. INFORMATICS ASS N 181, 181-82 (2011) . 214 Id. at 184 (stating that some physicians prefer the flexibility and expressivity of notes);; Ramakrishnan et al., supra note 196, at 96-215 Ramakrishnan et al., supra note 196, at 97. 216 Kohane, supra note 9, at 420. the software is complex and is developed by scientists or their assistants without the help of skilled software developers. 221 Inexperienced programmers are likely both to create incorrect software and to test it inadequately. 222 Even commercially developed biomedical research software, however, may produce erroneous results. 223 Ideally, scientists should work in close cooperation with software experts to develop and thoroughly validate software used in biomedical research.
IV.THE CHALLENGES OF BIAS AND CAUSAL INFERENCE
As argued above, the availability of large collections of data does not guarantee sound study outcomes. 224 Even if the data itself is unblemished, those analyzing it will face many obstacles to drawing correct conclusions from it. This Part analyzes subtle but important problems of bias affecting observational studies, in particular, selection bias, confounding bias, and measurement bias. An understanding of these issues is crucial for anyone seeking to interpret the results of biomedical database studies.
It is worth noting that one type of problem, namely sampling error, is less likely to be a major concern in observational studies based on large biomedical databases. Sampling error arises when inferences are drawn from observations of a randomly chosen sample of individuals whose statistical characteristics (e.g., smoking rate, average weight, or average duration of illness) differ from those of the source population due to random chance. 225 Conclusions drawn from the particular sample, therefore, cannot be accurately generalized to the population of interest. Sampling error tends to diminish as the sample size increases, and the extent of this error is well characterized by traditional statistical methods such as computation of confidence intervals. 226 Since the research databases contemplated in this Article are large and automatically queried, considerable samples can be processed efficiently to reduce sampling error. However, selection bias can nevertheless result if the individuals whose records are stored in a biomedical database and who satisfy the criteria for a given study do not constitute a random sample of the population targeted by the study. Selection bias may occur when the subset of individuals studied is not representative of the patient population of interest. 228 This kind of selection bias could manifest, for example, if a disproportionate number of people of one ancestry or economic class opt out of participating in a database. 229 It can likewise exist if individuals with certain behavior traits that might be important in some studies such as diet, exercise, smoking status, and alcohol or drug consumption choose not to participate or cannot access medical facilities in which studies take place. 230 Selection bias can distort assessments of measures such as disease prevalence or exposure risk because study estimates will differ systematically from the true values of these measures for the target population. 231 That is, the estimates will not be generalizable from the research subjects to the larger population about which analysts wish to draw conclusions. 232 Another, more -233 -234 -235 is specific to causal-effect studies. 236 These studies typically seek to measure the average beneficial effect on patients of a particular treatment or the average harmful effect on individuals of a particular exposure. 237 Collider-stratification bias occurs in analyzing study data when the analysis is conditioned on (e.g., stratified by) one or more levels of a variable that is a common effect variable and the outcome variable or that is a common effect of a cause of the treatment/exposure and a cause of the outcome. 238 Consider the following classic example. Commonly, some patients are lost to follow-up, and thus outcome measurements that would be essential for research purposes are unavailable. The data from these patients cannot be included in studies. Both the treatment and outcome at issue may influence which patients stop seeking medical care. Patients may fail to return for follow-up both because the treatment is need to return to their doctors (an outcome factor). The loss of these study subjects can create a spurious statistical association between the treatment/exposure variable and the outcome variable that becomes mixed with and distorts the true causal effect of the former on the latter. 239 Because collider-stratification bias is associated with the exclusion of some patients from a study, it is categorized as a type of selection bias. 240
B. CONFOUNDING BIAS
In observational causal-effect studies, confounding bias (confounding) may be an even greater concern than selection bias. 241 because of the presence of a common cause of the treatment/exposure variable and the outcome variable. 242 Confounding is different from collider-stratification bias because it involves a common cause of the treatment/exposure and outcome variables rather than a common effect of the variables. 243 The following hypothetical illustrates classical confounding. Suppose a disease, which also influence the outcome of treatment. 244 Thus, patients at a later stage of a disease may receive one treatment (treatment A) and those who are at an earlier stage may receive a different therapy (treatment B). At the same time, sicker patients may have worse treatment outcomes than healthier individuals. Unless such adjusted for appropriately during statistical data analysis, it may induce a spurious association between the treatment variable and the outcome variable, which distorts estimation of the true causal effects of treatments. 245 In other words, researchers may reach incorrect conclusions regarding the efficacy of the two treatments because of the confounding variable: the degree of sickness suffered by patients receiving the different therapies. Treatment A may appear to be less effective than treatment B not because it is in fact an inferior therapy but because so many of the patients receiving treatment A are in a late stage of the disease and would not do well no matter what 246 Socioeconomic factors and patient lifestyle choices may also be confounders. Those who lack financial resources or adequate health coverage may select less expensive treatments not because those are the best choices for them but because those are the only affordable options. 247 Low income may also separately lead to poor health for reasons such as poor nutrition or financial stress. In the case of oriented individuals interested in the intervention also pursue exercise, low-fat diets, and other healthwould not be associated solely with the preventive measure. 248 240 Collider-stratification bias may also occur because of a poorly conceived attempt to adjust for confounding bias, discussed below. Hernán et al., supra stratification is commonly used to adjust for confounding, it can have unintended effects 241 See Sander Greenland, Quantifying Biases in Causal Models: Classical Confounding vs. Collider-Stratification Bias, 14 EPIDEMIOLOGY 300, 306 (2003 Research, 304 J. AM. MED. ASS N 897, 897 (2010) . 245 Hernán et al., supra note 231, at 618. 246 See Jaclyn L.F. Bosco et al., A Most Stubborn Bias: No Adjustment Method Fully Resolves Confounding by Indication in Observational Studies, 63 J. CLINICAL EPIDEMIOLOGY 64, 70 (2010) . 247 See Brookhart et al., supra note 190, at S115. 248 Id.
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AMERICAN JOURNAL OF LAW & MEDICINE VOL. 39 NO. 4 2013 To reduce or eliminate confounding bias in an observational study, those conducting it must strive to ascertain, accurately measure, and adjust for all potential confounding variables. 249 In many studies, however, it is by no means clear which variables are potential confounders. Medical care is often dependent on a complex web of variables relating to the healthcare system, clinicians, and patients themselves, and the factors at work in each case may not be obvious. 250 Ideal randomized experiments, when they are feasible, prevent confounding because randomly assigning treatments to patients (possibly including a placebo) ensures there are no associations between the treatment variable and potential confounding variables. 251 In an observational study, investigators do not control treatment assignment because they review records that reflect treatments that have been previously administered. 252 Researchers must therefore attempt to obtain the values of confounding variables and adjust for them during analysis of the study data. 253 One option is to restrict the values of the confounding variables that is, to exclude subjects for whom the values of these variables are outside a chosen range in order to ensure that the treatment groups are similar to each other. 254 For example, in an observational study of the comparative effectiveness of diuretics and beta blockers for the prevention of heart attacks, researchers could minimize confounding by indication by restricting the analysis to patients without any evidence of clinical cardiovascular disease. 255 This restriction is desirable because among patients with cardiovascular disease, the use of beta blockers rather than diuretics is an indicator of more severe disease and greater pre-treatment risk of heart attack. 256 Pre-existing disease in those taking beta blockers could skew study results and make it difficult to ascertain the relative effectiveness of the two drugs. The disadvantage of this restriction is that the results obtained do not generalize directly to the entire population of patients taking diuretics or beta blockers, because many in fact have cardiovascular disease. 257 In some studies in which restriction is necessary, it is possible to generalize the results based on existing knowledge. 258 For example, although the causal link between smoking and lung cancer was established mainly through studies with male subjects, experts assumed the association existed in women too, because the lungs of men and women are anatomically similar. 259 In other cases, confounding bias can be controlled, without eliminating any groups of subjects from the analysis, by computing separate causal-effect estimates for each stratum (level) of a confounding variable. 260 Thus, if age is a confounder, analysts could calculate separate estimates for each ten-year interval of patient ages (birth to ten years old, ten to twenty years old, etc.). If the study cohort is representative of the target population, researchers can obtain an estimate of the average causal effect in the population by computing a 249 See ROTHMAN ET AL., supra note 225, at 158. 250 Brookhart et al., supra note 190, at S114. 251 Bosco et al., supra note 246, at 64 252 See, e.g., id. 253 Id. at 64-65. 254 Id. at 65. 255 Psaty & Siscovick, supra note 244, at 898. 256 Id. 257 Id.
258 ROTHMAN ET AL., supra note 225, at 146-47 (discussing generalizability). 259 Id. at 147. 260 Id. at 266. THE USE AND MISUSE OF BIOMEDICAL DATA 525 weighted average of the stratum-specific effect estimates, where the weight for each 261 C. MEASUREMENT BIAS Measurement biases arise from errors in measurement and data collection. 262 Observational study results may be compromised if the biomedical records that are analyzed contain such errors. Measurement errors occur for a variety of reasons. Measurement instruments might not be calibrated properly or might lack sufficient sensitivity to detect differences in relevant variables. 263 Storage time or conditions for biological samples might be different and might affect study results. 264 To the patience, and apparent sympathy or by the degree to which the patient perceives the topic to be important and relevant to her life. 265 In addition, patients may have impaired memories or may lie in response to questions if they are embarrassed about the truth. 266 Accurate measurement may be further hindered by incomplete, erroneous, or miscoded EHR data that obfuscates true values. 267 In causal-effect studies, errors in measurement of the treatment/exposure and the outcome are most problematic when they are associated (dependent) and when they are differential, that is, when the treatment affects the measurement error for the outcome or the outcome affects the measurement error for the treatment. 268 For example, differential measurement error could occur in a study of the effect of treatment A on dementia, if the use of A was determined only by interviewing study they were treated. 269 Mismeasurement of confounding variables also impedes adjustments intended to eliminate confounding bias. 270 V. BIOMEDICAL DATABASES AND PERSONAL AGENDAS Individuals with political, social, or economic agendas may exploit observational research outcomes to influence public opinion and legislative action. Manufacturers, for example, may fund studies regarding their products in the hope of generating new discoveries concerning the benefits of those products, thereby increasing their sales, 271 272 Data mining of biomedical databases may facilitate the discovery of statistical associations between use of certain products and the occurrence of desirable outcomes (e.g., lower disease risk). It is easy for marketers to imply that statistical associations are causal ones, even when the evidence for this is dubious because of confounding or other biases. 273 Those who are politically motivated may attempt to use data that appears scientific in order to pursue legislative or regulatory goals. This has already happened. As noted in the Introduction, a now-debunked study finding that abortions caused lasting psychological harm to women 274 was used by advocates to influence state legislatures. Consequently, several states enacted legislation that required clinicians to warn individuals who seek abortions that they could suffer future mental health ailments. 275 Needless to say, even highly trained researchers at academic institutions can produce low-quality work. The pressure to publish for tenure and promotion purposes or a desire for fame may tempt some faculty members to focus excessively on how publishable their work will be, at the expense of its scientific value. At least one study has explored whether publication pressures themselves generate biases among researchers and concluded that the answer is yes. 276 A review of 1316 papers found that United States researchers in competitive academic environments were tested. 277 likely to be published and subsequently cited. 278 This assumption may influence not only their choices as to which projects to pursue and which results to write up, but also, potentially, their objectivity in conducting research. 279 The dangers of misinterpretation, deliberate data distortion, flawed studies, and irresponsible use of research outcomes, might be acute if biomedical databases become publicly available. Individuals who have little research training but strong political voices and easy access to the media could deliberately misuse such databases.
As argued throughout this Article, amateurs are unlikely to produce reliable research outcomes. 280 Even leading scientists at times have difficulty interpreting research results and may disseminate confusing or misleading information to the public. A well-known example relates to the effect of postmenopausal hormone replacement therapy (HRT) on heart disease and breast cancer. 281 Data, 5 PLOS ONE 1, 4 (2010) . 277 Id. 278 Id. at 1. 279 Id. 280 See, e.g., supra Part IV. results of observational studies concerning HRT. 282 It was only with reanalysis of the data that the two were reconciled. Experts realized that the effect of HRT changed over time, which explained the apparent discrepancies. 283 In the end, scientists concluded that HRT increased the risk of both heart disease and breast cancer, but the cardiovascular risk was slightly higher for older women and the cancer risk was higher for women closer to menopause. 284 Yet, regardless of the quality of the work product, anyone can set up a website or blog and post documents that appear to be serious scientific studies. Moreover, these can quickly enjoy worldwide dissemination.
In addition, web-savvy people may employ strategies to increase the visibility of their messages. Even Google searches are vulnerable to manipulation through 285 286 Website owners can increase traffic to their sites by paying other websites to link to them. 287 They can also try to trick the search engine by showing Google crawlers 288 information that is different from that available to users. 289 Yet, many viewers will likely assume that studies that appear first or often in search-engine results are necessarily more credible and valuable than others.
VI. SOLUTIONS
We do not mean to suggest that biomedical databases are too flawed to be of value or that observational studies based on such databases are a lost cause. Quite to the contrary, we are optimistic about these emerging resources and capabilities. 290 The success of research initiatives, however, will depend on advances in technology as well as on human efforts to validate biomedical data and master the complexities of conducting sound observational studies. Anyone relying on record-based study outcomes, including government officials, attorneys, and the public at large, must section we propose technological enhancements, study-design and validation improvements, and educational initiatives to combat potential database and research inadequacies or abuses.
A. TECHNOLOGY IMPROVEMENTS
As EHR system technology matures, its capacity to capture accurate and comprehensive data sets should continue to improve. Health information technology 282 Vandenbroucke, supra note 79, at 1233. 283 Id. at 1233-34. 284 Id. at 1235. In addition, the risk of heart disease was found to increase in the first years of HRT use but then waned. Id. at 1234. & TECH. 188, 193 (2006) . 287 Facts about Google and Competition, GOOGLE, http://www.google.com/competition/howgooglesearchworks.html (last visited Oct. 22, 2013) . 288 supra note 285, at 481. 289 Goldman, supra note 286, at 193. 290 See Hoffman & Podgurski, supra note 8, at 97-102 (discussing the benefits of EHR-based research).
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AMERICAN JOURNAL OF LAW & MEDICINE VOL. 39 NO. 4 2013 request amendment in case of error. 327 Thus, this approach is novel only in that it would affirmatively encourage patients to scrutinize their medical files. Patients should submit error reports through 328 or a dedicated website so that they may create a record of their requests and document their assertions that errors exist. 329
Causal Inference Techniques
In the last two decades, researchers have made substantial progress in the development of a methodology for making causal inferences from observational data. Causal diagrams (also called causal graphs, directed acyclic graphs, or DAGs) are an important component of this methodology and have become a popular tool in the fields of statistics, biostatistics, epidemiology, and computer science. 330 The use of sound causal inference techniques is essential for analysis of large amounts of complex data from biomedical databases. Lawyers and policy officials would be well advised to keep abreast of causal research inference developments and be able to understand causal diagrams. Causation, Avoiding Bias, and Interpreting Results, 10 L. PROBABILITY & RISK 329, 329-30 (2011) . 331 VanderWeele & Staudt, supra note 330, at 333;; Jeffrey Swanson & Jennifer Ibrahim, Picturing Public Health Law Research: Using Causal Diagrams to Model and Test Theory , PUB. HEALTH L. RES. 1, 6 (2011) , http://publichealthlawresearch.org/sites/default/files/SwansonIbrahim -CausalDiagrams-March2012.pdf. 332 See supra note 307. 333 Swanson & Ibrahim, supra note 331, at 6. medical record or other sources. 334 A very simple causal diagram, reflecting the relationships between a treatment variable T, and outcome variable O, and a confounder C, is shown in Figure 1 . The assumptions about causal relationships between variables in a particular study or about the absence of such relationships. 335 relevant variables so that they can construct valid statistical models, avoid confounding, and correctly interpret study results. 336 In the process of creating causal diagrams, analysts attempt to specify the causal relationships and dependencies among all relevant factors involved in a particular problem, leaving the ultimate question of the relationship between the exposure of interest and the outcome to be discovered through research. 337 Causal diagrams can thus assist analysts in determining the measures to be used in a study and in understanding potential sources of bias. 338 They provide a clear, visual means to depict assumptions about the relationships of variables and highlight complexities that researchers might overlook in the absence of the graphs. 339 Moreover, researchers have derived precise conditions, in terms of a correct causal (statistically characterize) a given causal effect. 340 -Door -known example. 341 It characterizes the circumstances in which a set of variables is sufficient, if adjusted for, to eliminate confounding by the treatment/exposure variable and the outcome variable. 342 Note that an unblocked (open) back-door path permits a confounder to induce a spurious association between the treatment/exposure and the outcome. 343 Such conditions can be checked algorithmically, given a correctly specified causal diagram for a study. 344 In Figure  1 , the open back-door path T C O represents the ability of the variable C to confound estimation of the causal effect of the treatment variable T upon the outcome variable O. 345 This back-door path can be blocked by conditioning on (adjusting for) the confounder C, e.g., by restricting the analysis to a single level of C. 346 Returning to our previous example, suppose T indicates the drug a patient is given to treat high blood pressure (1: diuretic, 2: beta blocker);; C is an indicator for evidence of clinical cardiovascular disease (1: yes, 0: no);; and the outcome variable 334 Id.
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VanderWeele & Staudt, supra note 330, at 332. 336 Id. at 329. 337 Brookhart et al., supra note 190, at S116. 338 Id.; ; Swanson & Ibrahim, supra O indicates whether the patient had a heart attack after treatment (1: yes, 0: no). 347 Restricting the study to patients with C = 0, for whom there is no evidence of clinical cardiovascular disease, prevents distortion of the causal effect of T (treatment) on O (outcome) by a spurious, noncausal association between T and O. Such an association could occur because use of beta blockers, rather than diuretics, is an indicator of more severe disease and greater pre-treatment risk of heart attack. 348 Without such an adjustment, beta blockers could appear less effective than they really are because more of the patients taking them would likely suffer heart attacks caused by their existing cardiovascular disease. Confounding, selection bias, and measurement error may also affect observational studies of possible causal relationships between genes and diseases. 349 To address these challenges, researchers have advocated for the use of causal inference methodology, including causal diagrams, in genetic studies. 350 For example, systems biologists employ graphical models to depict what is known about the molecular networks by which genes regulate (or misregulate) the functioning of other genes. 351 The successful use of causal inference techniques in medical genetics is synergistically related to efforts to elucidate the complex biological networks by which genes influence disease. 352 If properly used, causal diagrams, and modern causal inference methodology more generally, can promote more accurate research results, which can lead to sound public health policies and regulations. Experts have also noted that causal graphs can be used to portray the relationship between the law and human behavior in order to ascertain that legal interventions are having the desired effect. 353 
